Assessing risk of bias in randomized controlled trials of methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Autor: Rodrigues-Tartari R; Department of Psychiatry, Universidade Federal de Sao Paulo, São Paulo, Brazil., Swardfager W; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.; Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.; University Health Network Toronto Rehabilitation Institute, Toronto, Canada., Salum GA; Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil., Rohde LA; Department of Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil., Cogo-Moreira H; Department of Psychiatry, Universidade Federal de Sao Paulo, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: International journal of methods in psychiatric research [Int J Methods Psychiatr Res] 2018 Mar; Vol. 27 (1). Date of Electronic Publication: 2017 Sep 04.
DOI: 10.1002/mpr.1586
Abstrakt: To test how reliable the tool recommend by Cochrane Collaboration for assessing risk of bias systematic reviews of randomized clinical trials is in the context of methylphenidate for children and adolescents with attention deficit hyperactivity disorder. Confirmatory factor analysis was used to evaluate a unidimensional model for the 7 indicators, applied to 184 Randomized Clinical Trial (RCTs) within a 2015 Cochrane systematic review titled "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder." A unidimensional model resulted in excellent adequacy indices, but only 2 indicators had very high factor loadings and low measurement errors. In terms of content, the 7 indicators showed poor reliability (ω = 0.642); however, the set of indicators was precise in evaluating studies with a high amount of bias risk. The Cochrane model of risk of bias as it is, exhibited good fit indices but the majority of the items were not reliable to adequately capture risk of bias in the context of clinical trials of methylphenidate for ADHD.
(Copyright © 2017 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje